questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Facteurs de transcription
Facteurs de transcription à domaine POU
Facteurs de transcription Oct
Facteur de transcription Oct-3
Facteur de transcription Oct-3 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Facteur de transcription Oct-3 : Questions médicales les plus fréquentes",
"headline": "Facteur de transcription Oct-3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Facteur de transcription Oct-3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-27",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Facteur de transcription Oct-3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Facteurs de transcription Oct",
"url": "https://questionsmedicales.fr/mesh/D050810",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs de transcription Oct",
"code": {
"@type": "MedicalCode",
"code": "D050810",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.930.710.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Facteur de transcription Oct-3",
"alternateName": "Octamer Transcription Factor-3",
"code": {
"@type": "MedicalCode",
"code": "D050814",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yang Yang",
"url": "https://questionsmedicales.fr/author/Yang%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Abdominal Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China."
}
},
{
"@type": "Person",
"name": "Hao Guo",
"url": "https://questionsmedicales.fr/author/Hao%20Guo",
"affiliation": {
"@type": "Organization",
"name": "Qiqihaer Medical University, Qiqihaer, Heilongjiang, 161005, PR China."
}
},
{
"@type": "Person",
"name": "Shuwei Hu",
"url": "https://questionsmedicales.fr/author/Shuwei%20Hu",
"affiliation": {
"@type": "Organization",
"name": "Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA."
}
},
{
"@type": "Person",
"name": "Rui Li",
"url": "https://questionsmedicales.fr/author/Rui%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China."
}
},
{
"@type": "Person",
"name": "Yanqiao Zhang",
"url": "https://questionsmedicales.fr/author/Yanqiao%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Ensuring environmental inclusion in developing countries: the role of macroeconomic policies.",
"datePublished": "2022-12-07",
"url": "https://questionsmedicales.fr/article/36474034",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11356-022-24596-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluating the quality of health technology assessment reports in a developing country.",
"datePublished": "2023-07-31",
"url": "https://questionsmedicales.fr/article/37553743",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.26719/emhj.22.017"
}
},
{
"@type": "ScholarlyArticle",
"name": "Investigating the impact of air pollution in selected African developing countries.",
"datePublished": "2023-04-17",
"url": "https://questionsmedicales.fr/article/37067712",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11356-023-26998-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "The national health program for vitamin D supplementation in a developing country.",
"datePublished": "2023-01-20",
"url": "https://questionsmedicales.fr/article/36963898",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clnesp.2023.01.012"
}
},
{
"@type": "ScholarlyArticle",
"name": "Addressing vaccine hesitancy in developing countries: Survey and experimental evidence.",
"datePublished": "2022-11-17",
"url": "https://questionsmedicales.fr/article/36395260",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0277493"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Facteurs de transcription",
"item": "https://questionsmedicales.fr/mesh/D014157"
},
{
"@type": "ListItem",
"position": 5,
"name": "Facteurs de transcription à domaine POU",
"item": "https://questionsmedicales.fr/mesh/D050809"
},
{
"@type": "ListItem",
"position": 6,
"name": "Facteurs de transcription Oct",
"item": "https://questionsmedicales.fr/mesh/D050810"
},
{
"@type": "ListItem",
"position": 7,
"name": "Facteur de transcription Oct-3",
"item": "https://questionsmedicales.fr/mesh/D050814"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Facteur de transcription Oct-3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Facteur de transcription Oct-3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Facteur de transcription Oct-3",
"description": "Comment diagnostiquer une anomalie d'Oct-3 ?\nQuels tests sont utilisés pour évaluer Oct-3 ?\nY a-t-il des biomarqueurs associés à Oct-3 ?\nQuels symptômes peuvent indiquer un problème avec Oct-3 ?\nComment l'expression d'Oct-3 est-elle mesurée ?",
"url": "https://questionsmedicales.fr/mesh/D050814?mesh_terms=Developing+Countries&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Facteur de transcription Oct-3",
"description": "Quels symptômes sont liés à une dysrégulation d'Oct-3 ?\nOct-3 influence-t-il le développement neurologique ?\nY a-t-il des symptômes associés à des cancers liés à Oct-3 ?\nComment Oct-3 affecte-t-il la fonction immunitaire ?\nDes anomalies de l'Oct-3 peuvent-elles causer des troubles métaboliques ?",
"url": "https://questionsmedicales.fr/mesh/D050814?mesh_terms=Developing+Countries&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Facteur de transcription Oct-3",
"description": "Peut-on prévenir les anomalies liées à Oct-3 ?\nY a-t-il des facteurs environnementaux influençant Oct-3 ?\nComment l'alimentation influence-t-elle Oct-3 ?\nDes exercices physiques peuvent-ils influencer Oct-3 ?\nQuelles sont les recommandations pour les femmes enceintes concernant Oct-3 ?",
"url": "https://questionsmedicales.fr/mesh/D050814?mesh_terms=Developing+Countries&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Facteur de transcription Oct-3",
"description": "Quels traitements ciblent Oct-3 dans le cancer ?\nPeut-on moduler Oct-3 par des médicaments ?\nY a-t-il des approches de thérapie cellulaire impliquant Oct-3 ?\nComment les thérapies géniques affectent-elles Oct-3 ?\nQuels sont les effets secondaires des traitements ciblant Oct-3 ?",
"url": "https://questionsmedicales.fr/mesh/D050814?mesh_terms=Developing+Countries&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Facteur de transcription Oct-3",
"description": "Quelles complications peuvent survenir avec des anomalies d'Oct-3 ?\nLes cancers liés à Oct-3 ont-ils des complications spécifiques ?\nComment les troubles d'Oct-3 affectent-ils la fertilité ?\nY a-t-il des complications neurologiques associées à Oct-3 ?\nLes troubles métaboliques liés à Oct-3 entraînent-ils des complications ?",
"url": "https://questionsmedicales.fr/mesh/D050814?mesh_terms=Developing+Countries&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Facteur de transcription Oct-3",
"description": "Quels sont les facteurs de risque pour les anomalies d'Oct-3 ?\nL'âge parental influence-t-il les risques liés à Oct-3 ?\nY a-t-il des maladies génétiques associées à Oct-3 ?\nLes habitudes de vie influencent-elles Oct-3 ?\nDes infections peuvent-elles affecter Oct-3 ?",
"url": "https://questionsmedicales.fr/mesh/D050814?mesh_terms=Developing+Countries&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie d'Oct-3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses d'expression génique peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer Oct-3 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunohistochimie et la PCR en temps réel sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à Oct-3 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux d'Oct-3 peuvent servir de biomarqueurs dans certaines pathologies."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec Oct-3 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies de développement ou des troubles de différenciation cellulaire peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment l'expression d'Oct-3 est-elle mesurée ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'expression peut être mesurée par RT-PCR ou Western blot pour quantifier la protéine."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une dysrégulation d'Oct-3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de la croissance et des anomalies morphologiques peuvent être observés."
}
},
{
"@type": "Question",
"name": "Oct-3 influence-t-il le développement neurologique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Oct-3 joue un rôle dans le développement du système nerveux central."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes associés à des cancers liés à Oct-3 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés selon le type de cancer, comme des douleurs ou des masses, peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment Oct-3 affecte-t-il la fonction immunitaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oct-3 régule l'expression des gènes impliqués dans la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Des anomalies de l'Oct-3 peuvent-elles causer des troubles métaboliques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dérèglements peuvent affecter le métabolisme cellulaire et énergétique."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies liées à Oct-3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance génétique et des conseils préconceptionnels peuvent aider à prévenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux influençant Oct-3 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains agents chimiques et radiations peuvent affecter l'expression d'Oct-3."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle Oct-3 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la régulation des facteurs de transcription comme Oct-3."
}
},
{
"@type": "Question",
"name": "Des exercices physiques peuvent-ils influencer Oct-3 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exercice régulier peut moduler l'expression de certains gènes, y compris Oct-3."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les femmes enceintes concernant Oct-3 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les toxines et suivre un suivi médical régulier peut aider à prévenir des anomalies."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent Oct-3 dans le cancer ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des inhibiteurs de signalisation peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on moduler Oct-3 par des médicaments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines molécules peuvent influencer l'expression d'Oct-3, mais la recherche est en cours."
}
},
{
"@type": "Question",
"name": "Y a-t-il des approches de thérapie cellulaire impliquant Oct-3 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des cellules souches modifiées exprimant Oct-3 sont explorées pour des thérapies."
}
},
{
"@type": "Question",
"name": "Comment les thérapies géniques affectent-elles Oct-3 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent corriger des mutations ou réguler l'expression d'Oct-3 dans les cellules."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ciblant Oct-3 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des réactions immunitaires et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies d'Oct-3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des malformations congénitales et des troubles du développement."
}
},
{
"@type": "Question",
"name": "Les cancers liés à Oct-3 ont-ils des complications spécifiques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme la métastase et la résistance au traitement peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les troubles d'Oct-3 affectent-ils la fertilité ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies peuvent entraîner des problèmes de fertilité et des complications de grossesse."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications neurologiques associées à Oct-3 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent résulter d'une dysrégulation d'Oct-3."
}
},
{
"@type": "Question",
"name": "Les troubles métaboliques liés à Oct-3 entraînent-ils des complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent causer des complications comme le diabète ou des maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies d'Oct-3 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux et des expositions environnementales sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge parental influence-t-il les risques liés à Oct-3 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé des parents peut augmenter le risque d'anomalies génétiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des maladies génétiques associées à Oct-3 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies comme le syndrome de Down peuvent être liées à des anomalies d'Oct-3."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles Oct-3 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme et l'alcool peuvent affecter l'expression d'Oct-3 et augmenter les risques."
}
},
{
"@type": "Question",
"name": "Des infections peuvent-elles affecter Oct-3 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent perturber l'expression d'Oct-3 dans les cellules."
}
}
]
}
]
}
In every society, there exist disadvantaged groups who have failed constantly to take part in the development of the economy and reap the benefits of economic growth as well. Along with economic and s...
No single method of health technology assessment (HTA) can meet all the policy- and decision-making needs in a country. However, there should be minimum criteria for performing HTA worldwide, and many...
This study aimed to assess the quality of HTA reports in the Islamic Republic of Iran....
We examined all the HTA research reports published by the Iranian HTA office up to 2020, using the International Network of Agencies for Health Technology Assessment checklist for quality assessment....
A total of 97 reports were examined, of which only 10.0% provided complete and appropriate contact details for further information and 5.6% clearly stated a conflict of interest. In 87.78% of the repo...
We recommend that minimum standards be established for the HTA process so that healthcare policy- and decision-makers can make reliable decisions on the basis of the HTA reports....
Air pollution is a major challenge faced by most countries due to the continuous quest of industrialization leading to a high pollution, which Africa is not an exception. Nowadays countries are trying...
Previous studies have reported a high frequency of vitamin D deficiency (VDD) among different age groups in Iran....
In this study, the current coverage, status of vitamin D supplement taking, and program efficacy have been evaluated by the Office of Nutrition Department Society in Iran since 2014....
This study was conducted in collaboration with the International UNESCO center for Health-Related Basic Sciences and Human Nutrition and the Office of Nutrition Department Society. Sixty three medical...
Quantitative analysis showed that availability coverage was 74.96% and 77.56% and accessibility was 80.70% and 83.26% in elderly and middle-aged subjects, respectively in 2018. The acceptability was a...
The frequency of taking vitamin D supplements was 27.0% in Iran in 2018. The frequency of taking of vitamin D supplements among vitamin D deficient group (serum vitamin D levels <19.99 ng/ml) was 43.6...
Vaccine hesitancy is proving to be a significant impediment to COVID-19 vaccination campaigns in some developing countries. This study focuses on vaccine hesitancy and means of reducing it. Data come ...
Pelonomi Tertiary Hospital is the only hospital in the Free State Province with a burns unit. We do not have official data to assess our performance in the management of burns....
To determine the Lethal Area 50 (LA50) index for the Pelonomi Tertiary Hospital's burns unit. Furthermore, to determine the morbidity that affects burns patients at the institution, and the factors as...
We used Redcap to capture demographic and clinical data of burn patients admitted to our institution between January 2014 and December 2018. Logistic regression was used to determine significant predi...
Our study had a male preponderance, with 59.7% (601) male, 39.9% (401) female and 0.4% (4) missing sex. We had a mean age of 19.4 years, of which 53.38% (n=537) were paediatric patients and 46.32% (n=...
The epidemiology of burn patients and working conditions at Pelonomi Tertiary Hospital are similar to other burn units in the country; however, our mortality rate is higher than at most centres. The L...
Technical aspects of inguinoscrotal herniorrhaphy performed in low to middle income countries (LMICs) are described here to help surgeons who will operate on these challenging hernias in austere setti...
Technical considerations related to operative repair were delineated with the consensus of 7 surgeons with extensive experience in inguinoscrotal hernia repair in LMICs. Important steps and illustrati...
The authors have cumulatively performed over 1775 inguinoscrotal Lichtenstein operations in LMICs. While dedicated, reliable, long-term follow-up is unavailable from LMICs, one author reports outcomes...
There is a difference between inguinal hernias found in LMICs and those seen in high-income countries with larger, chronic, and more technically challenging pathology. The consequences of intra-operat...
Growing populations, expanding economies, industrialisation, and urbanisation pose a problem for waste management in developing countries. Their waste management methods, on the other hand, are not as...
Considering the relevant role played by women in agriculture in Africa, this study sets out to examine how women's engagement in agriculture contributes to human capital development in selected Africa...
With increasing trend of internet use in all age groups, whether internet use can prevent frailty in middle-aged and older adults remains unclear....
Five cohorts, including Health and Retirement Study (HRS), China Health and Retirement Longitudinal Study (CHARLS), the Survey of Health, Ageing and Retirement in Europe (SHARE), English Longitudinal ...
In the multicohort study, a total of 155,695 participants were included in main analysis. The proportion of internet use was varied across countries, ranging from 5.56% in China (CHARLS) to 83.46% in ...
Our findings highlight the important role of internet use in preventing frailty and recommend more engagements in social communication and activities to avoid social isolation among middle-aged and ol...